**User testing paper: Supplementary Tables and figures**

**Supplementary Table 1:** Top 10 websites and countries directing most traffic to the webpages on “COVID-19 vaccines: key facts” and “COVID-19 vaccines: development, evaluation, approval and monitoring” from their date of publication until 30 April 2022.

|  |  |  |
| --- | --- | --- |
| **Top website sending traffic** | **COVID-19 vaccines: key facts** | **COVID-19 vaccines: development, evaluation, approval and monitoring** |
| 1st | [www.consillium.europa.eu](http://www.consillium.europa.eu) (EU) | ec.europa.eu (EU) |
| 2nd | ec.europa.eu (EU) | vaccinare-covid.gov.ro |
| 3rd | www.sukl.cz | www.adrreports.eu (EU) |
| 4th | www.adrreports.eu (EU) | www.consilium.europa.eu (EU) |
| 5th | www.hse.ie | www.gouvernement.fr |
| 6th | vaccinare-covid.gov.ro | www.diplomatie.gouv.fr  www.vaktsineeri.ee |
| 7th | www.gov.uk | www.mscbs.gob.es |
| 8th | www.diplomatie.gouv.fr | www.sukl.cz |
| 9th | www.jemevaccine.be | www.gov.uk |
| 10th | vaccination-info.eu | www.spth.gob.es |

**Supplementary Figure 1.** Usefulness of having key facts in another shareable material besides EMA webpage

EU-level (n=30) and regional (n=30) participants’ interest in having “COVID-19 vaccines: key facts” in a shareable document.

